Update shared on04 Aug 2025
Fair value Increased 17%The upward revision in Teradyne's consensus price target is primarily driven by stronger revenue growth projections and an increased forward P/E multiple, resulting in a new fair value estimate of $113.06.
What's in the News
- Teradyne expects Q3 2025 revenue between $710 million and $770 million, with GAAP net income of $0.62 to $0.80 per diluted share.
- The company was dropped from several Russell indexes, including the Russell Midcap Growth, Russell 1000 Growth, and Russell 3000 Growth.
- The Board amended and restated By-Laws, adjusting director nomination and shareholder proposal notice periods, updating shareholder nomination procedures, clarifying voting standards, and making various administrative updates.
Valuation Changes
Summary of Valuation Changes for Teradyne
- The Consensus Analyst Price Target has significantly risen from $97.81 to $113.06.
- The Consensus Revenue Growth forecasts for Teradyne has significantly risen from 11.3% per annum to 13.2% per annum.
- The Future P/E for Teradyne has risen from 20.73x to 22.45x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.